Pf601 Evolving Treatment Patterns in Multiple Myeloma (Mm) Differ by Age and Region: Analysis From Insight Mm, a Global, Prospective, Observational Study

Abstract

Conclusion:In summary, our data confirmed the favorable prognosis of the t(14; undefined) and no IgH groups, especially in the era of novel agents. Most importantly, translocation t(14; undefined) was identified as an independent protective factor for prolonged OS in multivariate analysis. Our study further validated the short survival of patients with t(4;14)/t(14;16), who are generally classified as high-risk disease; and conversely, indicated that survival of patients with t(11;14) is decreased relative to other patients with standard-risk disease.

Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS)

“…Although there continues to be no standard of care for RRMM in Europe [32], recent studies show that lenalidomide is often the most common treatment, and PI-based regimens, including triplets, are increasingly being prescribed [21,33]. Practice patterns in France differ from the rest of Europe, and only a few studies have reported on recent treatment patterns in RRMM that are specific to the French population [19,20].…”

Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma

“…In patients with newly diagnosed MM (NDMM), lenalidomide, bortezomib, and dexamethasone (RVd) is a frequently used standardof-care regimen for both transplant-eligible and transplant-ineligible patients, [1][2][3] and is one of the most common regimens in some geographies, notably the United States. 9 In previous studies of RVd, 3 including two phase 3 studies, 1,2,4 bortezomib was administered intravenously, per the route of administration at the time of initial approvals. However, intravenous bortezomib administration, particularly twice-weekly, has been associated with a high risk of peripheral neuropathy (PN).…”

“…Combinations incorporating these agents have proven highly effective in both the frontline 1–4 and relapsed, refractory 5–8 settings. In patients with newly diagnosed MM (NDMM), lenalidomide, bortezomib, and dexamethasone (RVd) is a frequently used standard‐of‐care regimen for both transplant‐eligible and transplant‐ineligible patients, 1–3 and is one of the most common regimens in some geographies, notably the United States 9 …”